Fybogel
Out of date information, search anotherSUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Senokot Hi-Fibre Orange Or
Fybogel Hi-Fibre Orange
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
A sachet contains 3.5g ispaghula husk BP.
3. PHARMACEUTICAL FORM
Effervescent granules.
4 CLINICAL PARTICULARS
4.1 Therapeutic Indications
For the treatment of patients requiring a high fibre regimen: for example, for the relief of constipation, including constipation in pregnancy and the maintenance of regularity; for the management of bowel function in patients with haemorrhoids.
4.2 Posology and Method of Administration
This medicine is intended for oral use as a suspension in a drink of water. The granules should be stirred into a glass of water and taken as soon as possible, preferably after meals. When preparing the product for administration, it is important to try to avoid inhaling any of the powder in order to minimize the risk of sensitization to the active ingredient.
Adults and children over 12 One sachet morning and evening. years:
Elderly:
There is no indication that dosage needs to be modified for the elderly.
Half to one level 5ml spoonful, depending on size and age, morning and evening.
Children aged 6 to 12 years:
Children under 6 years: To be taken only when prescribed by a doctor, half
to one level 5 ml spoonful depending on age and size, morning and evening.
The last dose should not be taken immediately before going to sleep If there has been no bowel movement after three days of treatment the doctor should be consulted.
4.3. Contraindications
This medicine is contraindicated in cases of intestinal obstruction, faecal impaction, natural or drug-induced reduction of gut motility and colonic atony such as senile megacolon.
Hypersensitivity to the active substance or to any of the excipients in the product (See Section 4.4 Special warnings and precautions for use)
4.4 Special Warnings and Special Precautions for Use
Warning on hypersensitivity reactions: In individuals with continued occupational contact to powder of Plantago ovata seeds (i.e. healthcare workers, caregivers) allergic sensitization may occur due to inhalation, this is more frequent in atopic individuals. This sensitization usually leads to hypersensitivity reactions which could be serious (see 4.8 Undesirable effects). It is recommended to assess clinically the possible sensitization of individuals at risk and, if justified, to perform specific diagnostic tests. In case of proven sensitization leading to hypersensitivity reactions, exposure to the product should be stopped immediately and avoided in the future (see
4.3 Contraindications).
If symptoms persist consult your doctor. Due to its aspartame content this medicine should not be given to patients with phenylketonuria.
Adequate fluid intake should be maintained. Therefore, they should always be taken with at least 150 mL of water or other liquid. The last dose should not be taken immediately before going to sleep since impaired or reduced gastric motility may impair the intestinal passage and then cause sub-obstruction.
4.5 Interactions with other Medicinal Products and other Forms of Interaction
Ispaghula and other bulk-forming laxatives may delay or reduce the gastrointestinal absorption of other drugs such as cardiac glycosides, coumarin derivatives, lithium, or vitamins (such as vitamin B12) and minerals (such as calcium, iron, or zinc).
4.6 Pregnancy and Lactation
This medicine may be used during pregnancy, since the ispaghula husk is not absorbed from the gastrointestinal tract.
4.7 Effects on Ability to Drive and Use Machines
None
4.8 Undesirable Effects
A small amount of abdominal distension and flatulence may sometimes occur. Ispaghula/psyllium husk contains potent allergens. The exposure to these allergens is possible through oral administration, contact with the skin and, in the case of powder formulations, also by inhalation. As a consequence to this allergic potential, individuals exposed to the product can develop hypersensitivity reactions such as rhinitis, conjunctivitis, bronchospasm and in some cases, anaphylaxia. Cutaneous symptoms as exanthema and/or pruritus have also been reported.
Special attention should be given to individuals manipulating the powder formulations routinely (see 4.4 Special warnings and precautions for use).
4.9 Overdose
In the event of overdosage conservative measures should be taken. The patient may notice abdominal discomfort and flatulence, and attention should be paid to maintaining an adequate fluid intake, particularly if the granules have been taken without water contrary to administration instructions.
5 PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic Properties
ATC Code: A06AC01
Ispaghula husk is capable of absorbing up to 40 times its own weight in water in vitro, and part of its activity can be attributed to its action as a simple bulking agent. In addition, colonic bacteria are believed to use the hydrated material as a metabolic substrate. This results in an increase in the bacterial cell mass with consequent softening of the faeces.
5.2 Pharmacokinetic Properties
The mode of action of this medicine is physical and does not depend on absorption into the systemic circulation.
5.3 Preclinical Safety Data
No preclinical findings relevant to the prescriber have been reported.
PHARMACEUTICAL PARTICULARS
6
6.1 List of excipients
|
Potassium bicarbonate |
USP |
|
Sodium bicarbonate |
Ph Eur |
|
Citric acid |
Ph Eur |
|
Riboflavine sodium phosphate |
Ph Eur |
|
Aspartame |
Ph Eur |
|
Orange flavour |
HSE |
|
Beta-carotene 10% CWS/S(E160a) |
HSE |
|
Saccharin Sodium |
Ph Eur |
|
Polysorbate 80 |
Ph Eur |
|
Silica colloidal anhydrous |
Ph Eur |
6.2 Incompatibilities
None known.
6.3 Shelf-Life
3 years.
6.4 Special Precautions for Storage
Store below 30°C in a dry place.
6.5 Nature and contents of container
7, 8, 10, 12, 14, 20, 24, 28 or 30 sachets enclosed in a cardboard outer. Polypropylene tubs with polyethylene lid containing 150 g of product.
6.6 Instructions for Use, Handling and Disposal
Senokot Hi-Fibre Orange granules are to be dispersed in water forming a drink.
7. MARKETING AUTHORISATION HOLDER
Reckitt Benckiser Healthcare (UK) Limited, Dansom Lane,
Hull,
HU8 7DS United Kingdom
8. MARKETING AUTHORISATION NUMBER(S)
PL 00063/0064
9. DATE OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
7th December 1998
10 DATE OF REVISION OF THE TEXT
13/03/14